# Biogen Reports Revenue Growth but Posts Quarterly Loss

Acquisition-related charges weighed on earnings as the company raised the lower end of its annual adjusted forecast.

By Will Langan | 24X7 News
Published: 2026-10-28T11:07:17.938Z
Updated: 2026-10-28T11:07:17.938Z
Section: Health
Format: News
Canonical: https://24x7news.us/articles/biogen-third-quarter-2026-results-october-28

Biogen reported an 11% increase in third-quarter revenue on October 28 but posted a loss of 14 cents per diluted share under standard accounting rules, according to its SEC-filed earnings release.

Revenue reached $2.8 billion, compared with $2.535 billion a year earlier. The company attributed the quarterly loss primarily to transaction-related charges. It had earned $3.17 per share in the corresponding 2025 quarter.

Adjusted earnings fell 46% to $2.62 per share. Both reported and adjusted results included $284 million in acquired research, upfront and milestone expenses, primarily associated with the RayThera acquisition.

Biogen said its Growth Portfolio generated $1.26 billion in revenue, up 49%, including the first full quarter of acquired Apellis products. Rare-disease revenue increased 27%, while multiple-sclerosis product revenue declined 13%.

The company lifted the lower end of its 2026 adjusted earnings forecast to $12.20 per share from $12.00, leaving the upper end at $13.00. Adjusted earnings are a supplemental, non-GAAP measure; the forecast remains a company projection.

Sources: Biogen earnings release filed with the SEC.

## Sources
- Biogen Third-Quarter 2026 Earnings Release, SEC Exhibit 99.1: https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm